

State of Vermont
Department of Vermont Health Access
280 State Drive, NOB 1 South
Waterbury, VT 05671-1010

Agency of Human Services
[Phone] 802-879-5903
[Fax] 802-879-5963
[Email] AHS.DVHAClinicalUnit@vermont.gov
www.dvha.vermont.gov

The Department of Vermont Health Access Clinical Criteria

Subject: Gene Expression Profiling for the Management of Breast Cancer

Last Review: August 30, 2024*

Past Revisions: May 5, 2023, January 26, 2021, September 1, 2020, August 14, 2019, June 19, 2019, June 1, 2018, November 1, 2017, August 26, 2015

***Please note: Most current content changes will be highlighted in yellow.**

Description of Service or Procedure

Gene expression profiling tests such as Oncotype DX® Breast Recurrence Score, EndoPredict®, Breast Cancer Index®, and MammaPrint®, are tools used to predict risk for recurrence of breast cancer and its response to therapy. These prognostic and predictive factors are relevant for patients diagnosed with early, non-metastatic breast cancer. Decisions can then be made regarding the addition of adjuvant chemotherapy to a treatment regimen or whether to treat with endocrine therapy alone.

Disclaimer

Coverage is limited to that outlined in Medicaid Rule or Health Care Administrative Rules that pertain to the member's aid category. Prior Authorization (PA) is only valid if the member is eligible for the applicable item or service on the date of service.

Medicaid Rule

Medicaid and Health Care Administrative Rules can be found at <https://humanservices.vermont.gov/rules-policies/health-care-rules/health-care-administrative-rules-hcar/adopted-rules>

- 7102.2 Prior Authorization Determination
- 7405 Lab and Radiology Services
- 4.101 Medical Necessity for Covered Services
- 4.104 Medicaid Non-Covered Services
- 4.106 Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Services



Coverage Position

Gene Expression Profiling using Oncotype DX® Breast Recurrence Score, EndoPredict®, Breast Cancer Index®, or MammaPrint® may be covered for members:

- When the service is prescribed by a licensed medical provider, enrolled in the Vermont Medicaid program, operating within their scope of practice as described on the Vermont Office of Professional Regulation's website*, Statute, or rule who is knowledgeable regarding gene expression profiling, and who provides medical care to the member AND
- When the clinical criteria below are met.

* Vermont's Office of Professional Regulation's website: <https://sos.vermont.gov/opr/>

Coverage Criteria

Gene expression profiling is covered by Vermont Medicaid in accordance with the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for breast cancer for the following tests:

- **Oncotype DX®**
- **EndoPredict®**
- **Breast Cancer Index®**
- **MammaPrint®**

Please find this guideline at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Considerations: Providers requesting this test should provide pre- and post-test genetic counseling for the member and family, if applicable.

Early and Periodic Screening, Diagnostic and Treatment (EPSDT) exception: Vermont Medicaid will provide comprehensive services and furnish all Medicaid coverable, appropriate, and medically necessary services needed to correct and ameliorate health conditions for Medicaid members under age 21.

Please note, Vermont Medicaid Clinical Criteria is reviewed based on available literature, evidence-based guidelines/standards, Medicaid rule and policy, and Medicare coverage determinations that may be appropriate to incorporate when applicable.

Clinical criteria for repeat service or procedure

One test per breast cancer diagnosis is approved.

Type of service or procedure not covered (this list may not be all inclusive)

The use of more than one type of test (if covered by Medicaid) to determine necessity of adjuvant therapy in breast cancer (Oncotype Dx® Breast, Breast Cancer Index®, EndoPredict®, Prosigna®, MammaPrint®) is considered experimental and investigational.

The use of these tests for any other purpose not outlined in this policy will not be covered.

Coding guidelines

Please see the Medicaid Portal at <http://vtmedicaid.com/#/feeSchedule> for fee schedules, code coverage, and applicable requirements.

References

- Andre, F., Ismaila, N., Allison, K.H., Barlow, W.E., Collyar, D.E., Damodaran, S., Henry, N.L., Jhaveri, K., Kalinsky, K., Kuderer, N.M., Litvak, A., Mayer, E.L., Puztai, L., Raab, R., Wolff, A.C., & Stearns, V. (2022). Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. *Journal of Clinical Oncology*, 40(16), 1816-1837. <https://doi.org/10.1200/JCO.22.00069>
- Centers for Medicare & Medicaid Services. (2023, April 27). *LCD - MoIDX: EndoPredict® Breast Cancer Gene Expression Test (L37663)*. Medicare Coverage Database. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37663&ver=18&keywordtype=starts&keyword=endopredict&bc=0>
- Centers for Medicare & Medicaid Services. (2023a, February 23). *LCD - MoIDX: Breast Cancer Index® (BCI) Gene Expression Test (L37913)*. Medicare Coverage Database. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37913&ver=13&keyword=breast%20cancer%20index&keywordType=starts&areald=s55&docType=NCA>
- Centers for Medicare & Medicaid Services. (2023b, May 4). *LCD - MoIDX: Molecular Diagnostic Tests (MDT) (L36256)*. Medicare Coverage Database. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=36256>
- Centers for Medicare & Medicaid Services. (2023c, October 26). *LCD - MoIDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) (L37199)*. Medicare Coverage Database. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37199&ver=14>
- Centers for Medicare and Medicaid Services. (2017). *Early and Periodic Screening, Diagnostic, and Treatment | Medicaid*. Medicaid.gov. <https://www.medicaid.gov/medicaid/benefits/early-and-periodic-screening-diagnostic-and-treatment/index.html>
- Foukakis, T., & Bergh, J. (2024, May 24). *Prognostic and predictive factors in early, non-metastatic breast cancer*. UpToDate. <https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-early-non-metastatic-breast-cancer>

- National Comprehensive Cancer Network. (2024, March 11). *NCCN clinical practice guidelines in oncology (NCCN Guidelines®) breast cancer version 2.2024*. Retrieved June 4, 2024, from https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- Qian, Y., Daza, J., Itzel T., Betge, J., Zhan, T., Marmé, F., & Teufel, A. (2021). Prognostic cancer gene expression signatures: current status and challenges. *Cells* 10(3), 648. <https://doi.org/10.3390/cells10030648>
- Rizki, H., Hillhar, C., Abbassi, O., & Miles-Dua-S. (2020). The utility of Oncotype DX for adjuvant chemotherapy treatment decisions in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, node-negative breast cancer. *Cureus*, 12(3), e7269. <https://doi.org/10.7759%2Fcureus.7269>
- Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., & Keane, M. M. (2019). Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. *New England Journal of Medicine*, 380(25), 2395–2405. <https://doi.org/10.1056/nejmoa1904819>
- Turner, B.M., Katerji, H., Zhang, H., & Hicks, D.G. (2021). Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. *Human Pathology Reports*, 21, 300574. <https://doi.org/10.1016/j.hpr.2021.300574>

This document has been classified as public information.